Written for executives and administrators in the pharmaceutical and biotechnology industries. Highlights all aspects of the pharmaceutical industry, including marketing, research and development and regulatory and legislative issues. Regular features include regulatory news, drug approvals, FDA advisory committee meetings, enforcement reports, business and marketing news, financial news and managed care developments.

BioCentury serves as the hub of several biotechnology publications, including BioCentury, the Bernstein Report on BioBusiness, BioCentury Extra, SciBX: Science-Business eXchange, BioCentury Week in Review and BioCentury Quarterly Stock Roundup. All content is original and created in-house using information from primary sources. The publication DOES NOT accept anything written by outside contributors (ie. contributed articles, white papers, etc.). Send press releases to the pressreleases@biocentury.com and longer pitches directly to Editors. This outlet offers RSS (Really Simple Syndication).

Established in 1981 and written for biotech and biopharma professionals involved in research, technical and commercial management. Provides coverage of biotechnology news and developments, scale-up and bioprocess technologies, regulatory and legal issues, new products and R&D and novel drug discovery techniques. Also includes financial news (public offerings, mergers and venture capital investments), funding and government news, corporate profiles, university news, meeting reports, international round-ups and literature information and articles relating to research projects and the production of biotechnology products.Regular topics in the publication include drug discovery technologies and R&D, trends in instrumentation, genomics and downstream omics, gene therapy, industrial biotechnology, enzymes, bioprocessing strategies, contract manufacture, monoclonal antibodies, bioinformatics, cell culture, LIMS, business issues and regulatory issues.Features the channels: Biobusiness which covers financial, business or patent related; Drug Discovery handles technical issues related to early stages of research and finding new pharmaceuticals; Omics spotlights genomics, proteomics and technologies such as metabolomics and Translational Medicine focuses on clinical and scientific efforts that concerns research and clinical settings. Other sections: Podcasts; Blogs; New Products; Best of the Web; GEN Updates RNAi; Oligonucleotides; Next-Generation Sequencing; Jobs; Classified Mart Marketplace; Real Estate; Conferences/Meetings; and Biotech Companies.The site offers RSS (Really Simple Syndication) and a digital Podcast.The publication DOES accept article submissions. Articles should be submitted to Managing Editor. Articles can be submitted either as POV articles, tutorials, overviews for the Transitional Medicine section, or online. For POV articles, they should be submitted one to two months in advance and should be about 1000 words. For tutorials, the articles should be submitted 4-6 months in advance and should be 1000-12000 words. For the Transitional Medicine section, these articles should be overviews, as opposed to specific points of view. They should also be 1000 words. For the online perspectives, they should be submitted a week before.

Life Science Leader is a B2B magazine for pharmaceutical, biotech, and biopharmaceutical executives.

Provides timely, in-depth news and analysis on biotechnology and the biotech industry. The fundamentals of working with bloggers are the same as with traditional journalists at traditional media outlets: respect their schedules; take time to read their material to learn their interests; and only contact them if/when they want to be contacted. You will also find that if a blogger is a journalist for another outlet(s), Cision tracks their contact preferences there as well. The outlet offers RSS (Really Simple Syndication).